Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 621 -69.50 (-10.07%)
As of 11:58 AM Eastern

HEMO vs. CIR, TILS, VSN, MPH, and 4BB

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? Hemogenyx Pharmaceuticals's main competitors and comparable companies include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Mereo BioPharma Group plc (MPH.L) (MPH), and 4basebio (4BB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Circassia Group (LON:CIR) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Circassia Group. Circassia Group's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Hemogenyx Pharmaceuticals Neutral

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -409.57%-37.79%

Circassia Group has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 0.9% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Circassia Group beats Hemogenyx Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Hemogenyx Pharmaceuticals (LON:HEMO) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.76 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Tiziana Life Sciences Positive

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -409.57% -37.79%
Tiziana Life Sciences N/A N/A N/A

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 0.9% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tiziana Life Sciences has lower revenue, but higher earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

Summary

Tiziana Life Sciences beats Hemogenyx Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Verseon?

Verseon (LON:VSN) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -409.57%-37.79%

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 0.9% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Verseon. Verseon's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Verseon Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Hemogenyx Pharmaceuticals beats Verseon on 4 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Hemogenyx Pharmaceuticals N/A -409.57%-37.79%

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 0.9% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Mereo BioPharma Group plc (MPH.L). Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Mereo BioPharma Group plc (MPH.L) beats Hemogenyx Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to 4basebio?

4basebio (LON:4BB) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

4basebio currently has a consensus price target of GBX 1,400, indicating a potential upside of 170.53%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Hemogenyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Hemogenyx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than 4basebio. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£781K102.61-£9.84M-£116.00N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A

In the previous week, 4basebio and 4basebio both had 1 articles in the media. 4basebio's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
4basebio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hemogenyx Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Comparatively, 0.9% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

4basebio has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, suggesting that its share price is 49% more volatile than the broader market.

4basebio's return on equity of -231.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
Hemogenyx Pharmaceuticals N/A -409.57%-37.79%

Summary

4basebio beats Hemogenyx Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

MetricHemogenyx PharmaceuticalsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£42.83M£3.94B£7.46B£2.68B
Dividend YieldN/A3.64%2.48%5.11%
P/E Ratio-4.7523.6032.5322.78
Price / SalesN/A15.638.104.91
Price / Cash2.0522.6520.7220.23
Price / Book2,520.714.144.322.40
Net Income-£6.89K-£24.03M£3.51B£5.88B
7 Day Performance-10.12%-9.19%-7.64%-3.52%
1 Month Performance-10.00%-13.05%-10.10%-4.94%
1 Year Performance-24.92%-5.90%-2.55%4.49%

Hemogenyx Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 621
-10.1%
N/A-24.7%£42.83MN/AN/A14
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50

Related Companies and Tools


This page (LON:HEMO) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners